文献速递腹部技术与安全CT

局限性胰腺癌诊断时不确定性肝病变的特征分析

Characterizing indeterminate liver lesions in patients with localized pancreatic cancer at the time of diagnosis.
PubMed 文献 · Abdom Radiol (NY) · 2018-01-01

本回顾性研究纳入2008至2015年304例局限性非转移性胰腺癌患者,评估治疗前CT肝病变并建立分类系统(肯定良性、不确定可能良性2B、不确定可能恶性2M)。中位随访56周,8例(9%)不确定病变进展为明确肝转移;分类系统敏感度38%、特异度91%、阳性预测值30%、阴性预测值94%。

要点

  • 局限性胰腺癌诊断时41%(125/304)存在肝病变,其中72%(90/125)为不确定性病变。
  • 不确定病变中89%(80/90)归为2B、11%(10/90)归为2M,2B进展为肝转移5/80(6%),2M为3/10(30%)。
  • 分类系统敏感度38%、特异度91%、阳性预测值30%、阴性预测值94%。

核心结论

  • 相当比例的局限性胰腺癌患者在诊断时存在肝病变,且多数为不确定性特征;按恶性潜能进一步分层的不确定肝病变分类系统与高阴性预测值相关,可辅助临床确定最佳治疗方案。

研究设计与样本

  • 回顾性研究,纳入2008至2015年304例局限性非转移性胰腺癌患者,评估治疗前CT扫描有无肝病变,并将肝病变分为肯定良性(1)或不确定(2);不确定病变再分为不确定可能良性(2B)或不确定可能恶性(2M),随访影像评估指标肝病变稳定或明确疾病进展。

关键影像表现/征象

  • 304例患者中125例(41%)存在肝病变,35例(28%)病变归为肯定良性,90例(72%)归为不确定。
  • 90例不确定病变中80例(89%)归为2B,10例(11%)归为2M。
  • 中位随访56周,肯定良性病变患者无指标病变转移进展;不确定病变中8例(9%)指标病变进展为明确肝转移,其中2B组5/80(6%),2M组3/10(30%)。

诊断标准与关键数值

  • 肝病变分类:肯定良性(1)或不确定(2);不确定病变再分为不确定可能良性(2B)或不确定可能恶性(2M)。
  • 分类系统敏感度38%、特异度91%、阳性预测值30%、阴性预测值94%。

临床应用与阅片要点

  • 对局限性胰腺癌患者治疗前CT上的肝病变,可按肯定良性、不确定可能良性(2B)、不确定可能恶性(2M)进行分类,以评估恶性风险。
  • 分类系统阴性预测值94%,有助于识别进展风险低的病变。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: In patients with newly diagnosed pancreatic cancer, the classification of indeterminate liver lesions is an unanswered clinical dilemma as misclassification of these lesions can impact the assignment of clinical stage and subsequent treatment planning. Our objective was to design a standardized classification system to more accurately define the risk of malignancy in indeterminate liver lesions.

METHODS: In this retrospective study, patients with localized, non-metastatic pancreatic cancer were identified and pre-treatment computed tomography (CT) scans were evaluated for the presence or absence of liver lesions. Liver lesions were defined as definitely benign (1) or indeterminate (2). Indeterminate lesions were further sub-classified as either indeterminate probably benign (2B) or indeterminate possibly malignant (2M). The index liver lesion was evaluated on follow-up imaging for stability or unequivocal disease progression.

RESULTS: From 2008 to 2015, 304 patients with localized, non-metastatic pancreatic cancer were identified and 125 (41%) patients had liver lesions. Of the 125 patients, the liver lesions in 35 (28%) were classified as definitely benign and in 90 (72%) patients they were classified as indeterminate. The 90 patients with indeterminate lesions included 80 (89%) classified as indeterminate probably benign (2B) and 10 (11%) classified as indeterminate possibly malignant (2M). After a median follow-up of 56 weeks, no patient with a definitely benign lesion had metastatic disease progression of the index lesion. Of the 90 patients with indeterminate liver lesions, the index lesion progressed to unequivocal liver metastasis in 8 (9%) patients; 5 (6%) of the 80 lesions classified as indeterminate probably benign (2B), and 3 (30%) of the ten lesions classified as indeterminate possibly malignant (2M). The sensitivity of the classification system was 38% and the specificity was 91%. The positive predictive value was 30% and the negative predictive value was 94%.

CONCLUSIONS: A significant proportion of patients with localized pancreatic cancer will have liver lesions identified at the time of diagnosis and most of these lesions will have indeterminate characteristics. A classification system which further stratifies indeterminate liver lesions by malignant potential can assist clinicians in determining optimal treatment plan and is associated with a high negative predictive value.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Bhalla M, Aldakkak M, Kulkarni NM, et al. Characterizing indeterminate liver lesions in patients with localized pancreatic cancer at the time of diagnosis. Abdom Radiol (NY). 2018. PMID: 29185014. doi:10.1007/s00261-017-1404-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。